Document is current

Article History

Received: 12 November 2021

Accepted: 7 June 2022

First Online: 24 June 2022

Declarations

:

: This study uses monkeys and experimental protocols that have been approved by IACUC of USC (see the “Materials and Methods” section for details).

: Not applicable.

: JOJ is founder and CEO of Artery Therapeutics, Inc. JOJ and JJ receive salary from and hold stock in Artery Therapeutics. JOJ is a co-inventor of CS6253 composition of matter and method of use patents. The relevant US patent is US 9416162 B2 with JOJ as an inventor. This does not alter the authors' adherence to all the publication policies on sharing data and materials. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The authors declare no other competing financial interests.